LEADER 01026nam0-22002891i-450- 001 990007915230403321 005 20041014124807.0 035 $a000791523 035 $aFED01000791523 035 $a(Aleph)000791523FED01 035 $a000791523 100 $a20040914d2003----km-y0itay50------ba 101 0 $aita 102 $aIT 105 $aa-------001yy 200 1 $a<>strategia di ripartizione dei fondi di incentivazione dei professori e dei ricercatori universitari$fdi Michele Lalla 210 $aModena$cUniversità di Modena. Dipartimento di Economia Politica$d2003 215 $a30 p.$d30 cm 225 1 $aMateriali di discussione$fDipartimento di economia politica. Università di Modena$v428 700 1$aLalla,$bMichele$0126765 801 0$aIT$bUNINA$gRICA$2UNIMARC 901 $aBK 912 $a990007915230403321 952 $aPaper 57/428$fSES 959 $aSES 996 $aStrategia di ripartizione dei fondi di incentivazione dei professori e dei ricercatori universitari$9670072 997 $aUNINA LEADER 01580cam0-22005651i-450- 001 990000419060403321 005 20081031085714.0 035 $a000041906 035 $aFED01000041906 035 $a(Aleph)000041906FED01 035 $a000041906 100 $a20020821d1971----km-y0itay50------ba 101 1 $aita$ceng 102 $aIT 105 $ay-------001yy 200 1 $aFilosofia e scienza dei sistemi$fC. West Churchman$gintroduzione di Romano Trabucchi$gtraduzione di Luciano Ongaro 210 $aMilano$cILI$d1971 215 $axl, 271 p.$d19 cm 225 1 $aCampus$v6 454 0$12001$aChallenge to reason$939054 610 0 $aFilosofia della scienza 610 0 $aEpistemologia 610 0 $aSistemi$aTeorie 610 0 $aScienza dei sistemi 610 0 $aRicerca operativa 676 $a501 676 $a003.01 700 1$aChurchman,$bCharles West$f<1913- >$02743 702 1$aOngaro,$bLuciano 702 1$aTrabucchi,$bRomano 801 0$aIT$bUNINA$gRICA$2UNIMARC 901 $aBK 912 $a990000419060403321 952 $a2-4-37-TI$bs.i.$fECA 952 $a9-11-10$bS.I.$fECA 952 $a11350 CHU$b3990/I$fSES 952 $a501 CHU 1$b763$fBFS 952 $aP.1 FS 150$bIst. st. fil. 3596$fFLFBC 952 $a08 L 5$b6127 (AT)$fDINED 952 $a05 FE 13 101$b2365$fDININ 952 $a01 DC 3009$b4040$fDINST 959 $aDINED 959 $aDININ 959 $aDINST 959 $aECA 959 $aSES 959 $aBFS 959 $aFLFBC 996 $aChallenge to reason$939054 997 $aUNINA LEADER 03596nam 2200445z- 450 001 9910136798703321 005 20210212 035 $a(CKB)3710000000631135 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/58943 035 $a(oapen)doab58943 035 $a(EXLCZ)993710000000631135 100 $a20202102d2015 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aThe Schistosomiasis Vaccine - It Is Time to Stand Up 210 $cFrontiers Media SA$d2015 215 $a1 online resource (82 p.) 225 1 $aFrontiers Research Topics 311 08$a2-88919-741-7 330 $aSchistosomiasis is a severe parasitic disease, endemic in 74 developing countries with up to 600 million people, including many children, infected and 800 million at risk of contracting the disease following infection with Schistosoma mansoni, S. haematobium or S. japonicum. Disease burden is estimated to exceed 70 million disability-adjusted life-years, and leads to remarkably high YLD (years lived with disability) rates. Even more importantly, people with schistosomiasis are highly susceptible to malaria, tuberculosis and hepatic and acquired immunodeficiency viruses. There is only one drug, praziquantel, currently available for treatment and it has high efficacy, low cost, and limited side effects. However, only 13% of the target population has received the drug, and those treated are at continuous risk of reinfection necessitating repeated drug administration and the emergence of drug resistant parasites is a constant threat. There currently is no vaccine. While the target of >40% protection has been achieved with some molecules such as excretory-secretory proteins including calpain, glyceraldehyde 3-phosphate dehydrogenase, and cysteine peptidases, very recent articles reiterate the findings published during the last 2 decades of the last century, contradicting the established data of the pioneers of schistosome biology. A consensus should be reached without delay, in order to propose collaborative independent experiments and proceed ahead to pre- and clinical trials with efficacious candidate vaccine molecules. The proposed plan aims to finally reach an objective and fruitful agreement , via inviting established and young researchers from the United States, Brazil, China, Australia, and Europe who are working with different vaccine antigens, adjuvants, and approaches for immunization against S. mansoni, S. haematobium, and S. japonicum. It is hoped that the forum will end with a very few candidate antigens and a consensus approach regarding target immune responses, thus leading to encouraging the World Health Organization and other international foundations to sponsor the development and implementation of the urgently required, yet still elusive, vaccine for preventing and eliminating the transmission of schistosomiasis. 606 $aMedicine and Nursing$2bicssc 610 $aImmune responses 610 $aSchistosoma haematobium 610 $aSchistosoma japonicum 610 $aSchistosoma mansoni 610 $aSchistosomiasis 610 $aType 2 cytokines 610 $aVaccine 610 $aVaccine candidates 615 7$aMedicine and Nursing 700 $aAhmad Ali Othman$4auth$01278948 702 $aDonald McManus$4auth 702 $aRashika El Ridi$4auth 906 $aBOOK 912 $a9910136798703321 996 $aThe Schistosomiasis Vaccine - It Is Time to Stand Up$93014275 997 $aUNINA